Wednesday, July 22, 2020, 5:00 PM – 6:00 PM ET
Recent Advances in Medical Oncology: MelanomaJoin us on Wednesday, July 22 for the live webinar Complimentary Registration Faculty
Michael B Atkins, MD Deputy Director, Georgetown Lombardi Comprehensive Cancer Center William M Scholl Professor and Vice-Chair, Department of Oncology Professor of Medicine Georgetown University Medical Center Washington, DC Jason J Luke, MD Associate Professor and Director of the Cancer Immunotherapeutics Center University of Pittsburgh Medical Center and Hillman Cancer Center Pittsburgh, Pennsylvania Professor Georgina Long, AO, BSc, PhD, MBBS Co-Medical Director of Melanoma Institute Australia Chair of Melanoma Medical Oncology and Translational Research Melanoma Institute Australia and Royal North Shore Hospital The University of Sydney Sydney, Australia Moderator Neil Love, MD Research To Practice Miami, Florida Supporters This activity is supported by educational grants from Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, and Merck. Evolving Treatment Approaches for Patients with Localized or Locally Advanced Melanoma — Prof Long
Integration of BRAF/MEK Inhibitors into the Management of Metastatic Melanoma with a BRAF Tumor Mutation — Jason J Luke, MD
Current and Future Role of Immune Checkpoint Inhibitors in the Management of Metastatic Melanoma, Including Those with CNS Metastases — Michael B Atkins, MD
Target Audience Learning Objectives
CME Credit Form Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Content Validation and Disclosures FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Atkins — Advisory Committee: Arrowhead Pharmaceuticals, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Idera Pharmaceuticals Inc, Leads Biolabs, Merck, Novartis, PACT Pharma, Pfizer Inc, Pneuma Medical, Pyxis Oncology, Roche Laboratories Inc, Werewolf Therapeutics; Consulting Agreements: Agenus Inc, Apexigen, COTA, Immunocore, Iovance Biotherapeutics, Neoleukin Therapeutics, Third Rock Ventures; Contracted Research (to Institution): Bristol-Myers Squibb Company, Merck; Data and Safety Monitoring Board/Committee: Novartis, PACT Pharma; Ownership Interest: Pyxis Oncology, Werewolf Therapeutics. Prof Long — Consultant Advisor: Aduro Biotech, Agena Bioscience Inc, Amgen Inc, Bristol-Myers Squibb Company, Highlight Therapeutics, Merck, Merck Sharp & Dohme Corp, Novartis, OncoSec Medical, Pierre Fabre, QBiotics Group, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Skyline Pharmaceuticals Inc. Dr Luke — Advisory Committee: 7 Hills Pharma LLC, AbbVie Inc, Actym Therapeutics, Alphamab Oncology, Pyxis Oncology, Spring Bank Pharmaceuticals Inc, Tempest Therapeutics Inc; Consulting Agreements: AbbVie Inc, Akrevia Therapeutics, Aligos Therapeutics, Array BioPharma Inc, Astellas, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, EMD Serono Inc, IDEAYA Biosciences, Incyte Corporation, Janssen Biotech Inc, Merck, Mersana Therapeutics, Novartis, RefleXion, Silicon Therapeutics, Tesaro, A GSK Company, Vividion Therapeutics; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Checkmate Pharmaceuticals, Compugen Inc, Corvus Pharmaceuticals, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, Genentech, Immatics Biotechnologies GmbH, Immunocore, Incyte Corporation, Leap Therapeutics Inc, MacroGenics Inc, Merck, Nektar, Novartis, Palleon Pharmaceuticals, RAPT Therapeutics, Spring Bank Pharmaceuticals Inc, Tesaro, A GSK Company, Tizona Therapeutics Inc, Xencor; Data and Safety Monitoring Board/Committee: TTC Oncology; Paid Travel: Akrevia Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Mersana Therapeutics, Novartis, Pyxis Oncology, RefleXion; Ownership Interest: AbbVie Inc, Actym Therapeutics, Alphamab Oncology, Pyxis Oncology, Tempest Therapeutics Inc.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |